Background: Daily trimethoprim-sulfamethoxazole (TMP-SMX) and insecticide-treated nets remain the main interventions for prevention of malaria in human immunodeficiency virus (HIV)-infected pregnant women in Africa. However, antifolate and pyrethroid resistance threaten the effectiveness of these interventions, and new ones are needed. Methods: We conducted a double-blinded, randomized, placebo-controlled trial comparing daily TMP-SMX plus monthly dihydroartemisinin-piperaquine (DP) to daily TMP-SMX alone in HIV-infected pregnant women in an area of Uganda where indoor residual spraying of insecticide had recently been implemented. Participants were enrolled between gestation weeks 12 and 28 and given an insecticide-treated net. The primary outcome was detection of active or past placental malarial infection by histopathologic analysis. Secondary outcomes included incidence of malaria, parasite prevalence, and adverse birth outcomes. Result: All 200 women enrolled were followed through delivery, and the primary outcome was assessed in 194. There was no statistically significant difference in the risk of histopathologically detected placental malarial infection between the daily TMP-SMX plus DP arm and the daily TMP-SMX alone arm (6.1% vs. 3.1%; relative risk, 1.96; 95% confidence interval, .50-7.61; P = .50). Similarly, there were no differences in secondary outcomes. Conclusions: Among HIV-infected pregnant women in the setting of indoor residual spraying of insecticide, adding monthly DP to daily TMP-SMX did not reduce the risk of placental or maternal malaria or improve birth outcomes. Clinical Trials Registration: NCT02282293.
RCT Entities:
Background: Daily trimethoprim-sulfamethoxazole (TMP-SMX) and insecticide-treated nets remain the main interventions for prevention of malaria in human immunodeficiency virus (HIV)-infected pregnant women in Africa. However, antifolate and pyrethroid resistance threaten the effectiveness of these interventions, and new ones are needed. Methods: We conducted a double-blinded, randomized, placebo-controlled trial comparing daily TMP-SMX plus monthly dihydroartemisinin-piperaquine (DP) to daily TMP-SMX alone in HIV-infected pregnant women in an area of Uganda where indoor residual spraying of insecticide had recently been implemented. Participants were enrolled between gestation weeks 12 and 28 and given an insecticide-treated net. The primary outcome was detection of active or past placental malarial infection by histopathologic analysis. Secondary outcomes included incidence of malaria, parasite prevalence, and adverse birth outcomes. Result: All 200 women enrolled were followed through delivery, and the primary outcome was assessed in 194. There was no statistically significant difference in the risk of histopathologically detected placental malarial infection between the daily TMP-SMX plus DP arm and the daily TMP-SMX alone arm (6.1% vs. 3.1%; relative risk, 1.96; 95% confidence interval, .50-7.61; P = .50). Similarly, there were no differences in secondary outcomes. Conclusions: Among HIV-infected pregnant women in the setting of indoor residual spraying of insecticide, adding monthly DP to daily TMP-SMX did not reduce the risk of placental or maternal malaria or improve birth outcomes. Clinical Trials Registration: NCT02282293.
Authors: Moses R Kamya; Emmanuel Arinaitwe; Humphrey Wanzira; Agaba Katureebe; Chris Barusya; Simon P Kigozi; Maxwell Kilama; Andrew J Tatem; Philip J Rosenthal; Chris Drakeley; Steve W Lindsay; Sarah G Staedke; David L Smith; Bryan Greenhouse; Grant Dorsey Journal: Am J Trop Med Hyg Date: 2015-03-16 Impact factor: 2.345
Authors: Jeanne Rini Poespoprodjo; Wendy Fobia; Enny Kenangalem; Daniel A Lampah; Paulus Sugiarto; Emiliana Tjitra; Nicholas M Anstey; Ric N Price Journal: PLoS One Date: 2014-01-17 Impact factor: 3.240
Authors: Mary K Muhindo; Abel Kakuru; Paul Natureeba; Patricia Awori; Peter Olwoch; John Ategeka; Patience Nayebare; Tamara D Clark; Atis Muehlenbachs; Michelle Roh; Betty Mpeka; Bryan Greenhouse; Diane V Havlir; Moses R Kamya; Grant Dorsey; Prasanna Jagannathan Journal: Malar J Date: 2016-08-26 Impact factor: 2.979
Authors: Kiran T Thakur; Alexandra Boubour; Deanna Saylor; Mitashee Das; David R Bearden; Gretchen L Birbeck Journal: AIDS Date: 2019-02-01 Impact factor: 4.177
Authors: Michelle E Roh; Stephen Shiboski; Paul Natureeba; Abel Kakuru; Mary Muhindo; Teddy Ochieng; Albert Plenty; Catherine A Koss; Tamara D Clark; Patricia Awori; Miriam Nakalambe; Deborah Cohan; Prasanna Jagannathan; Roly Gosling; Diane V Havlir; Moses R Kamya; Grant Dorsey Journal: J Infect Dis Date: 2017-12-19 Impact factor: 5.226
Authors: Xin Hui S Chan; Yan Naung Win; Laura J Mawer; Jireh Y Tan; Josep Brugada; Nicholas J White Journal: Lancet Infect Dis Date: 2018-06-18 Impact factor: 71.421
Authors: John Ategeka; Razack Wasswa; Peter Olwoch; Abel Kakuru; Paul Natureeba; Atis Muehlenbachs; Moses R Kamya; Grant Dorsey; Gabrielle Rizzuto Journal: PLoS One Date: 2019-04-11 Impact factor: 3.240
Authors: Xin Hui S Chan; Yan Naung Win; Ilsa L Haeusler; Jireh Y Tan; Shanghavie Loganathan; Sompob Saralamba; Shu Kiat S Chan; Elizabeth A Ashley; Karen I Barnes; Rita Baiden; Peter U Bassi; Abdoulaye Djimde; Grant Dorsey; Stephan Duparc; Borimas Hanboonkunupakarn; Feiko O Ter Kuile; Marcus V G Lacerda; Amit Nasa; François H Nosten; Cyprian O Onyeji; Sasithon Pukrittayakamee; André M Siqueira; Joel Tarning; Walter R J Taylor; Giovanni Valentini; Michèle van Vugt; David Wesche; Nicholas P J Day; Christopher L-H Huang; Josep Brugada; Ric N Price; Nicholas J White Journal: PLoS Med Date: 2020-03-05 Impact factor: 11.069